Constantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease Therapies

▤ Summary

Constantiam Biosciences and Cincinnati Children’s formed a strategic collaboration to advance first-in-class therapies for neuronopathic Gaucher disease. The deal includes an exclusive option for future licensing rights tied to small-molecule treatments and combines Cincinnati Children’s translational research with Constantiam’s RareScan functional genomics platform. Constantiam is also raising a seed round to support IND-enabling work and first-in-human trials. The arrangement aims to match therapeutic candidates to patient genotypes and reduce risk in rare-disease drug development.

▦ Linked Companies